Introduction: Hypertension is a complex and multifactorial cardiovascular disorder. With different mechanisms contributing to a different extent to an individual’s blood pressure the discovery of novel pathogenetic principles of hypertension is challenging. However, there is an urgent and unmet clinical need to improve prevention, detection and therapy of hypertension in order to reduce the global burden associated with hypertension-related cardiovascular diseases.
Areas covered: Proteomic techniques have been applied in reductionist experimental models including angiotensin II infusion models in rodents and the spontaneously hypertensive rat in order to unravel mechanisms involved in blood pressure control and end organ damage. In humans proteomic studies mainly focus on prediction and detection of organ damage, particularly of heart failure and renal disease. Whilst there are only few proteomic studies specifically addressing human primary hypertension there are more data available in hypertensive disorders in pregnancy such as preeclampsia. We will review these studies and discuss implications of proteomics on precision medicine approaches.
Expert commentary: Despite the potential of proteomic studies in hypertension there has been moderate progress in this area of research. Standardised large-scale studies are required in order to make best use of the potential that proteomics offers in hypertension and other cardiovascular diseases
